Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02431845 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT02431845 · ClinicalTrials.gov record · last posted 2024-12-27

Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder

StatusRecruiting
PhaseNot applicable
Started2013-01-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to determine whether pharmaco(epi)genetic study predict selective serotonin reuptake inhibitor (SSRI) responsiveness in advance before the appearance of the drug effect until 4 months(16 weeks), 6 months, and 1 year after administration of SSRIs.

Amendment record 8 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 8 times since 2015-04-27; most recent amendment 2024-12-24. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT02431845
Lead Sponsor Severance Hospital
Conditions Obsessive-Compulsive Disorder
Enrollment 200 participants
Start Date 2013-01-01
Primary Completion 2030-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-27